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Abstract
The chapter is a review of current knowledge on the impact of H. pylori infection on 
the clinical course of patients with various forms of liver damage. H. pylori infection is 
found in 50–90% of the world population. The bacteria not only mainly contribute to 
occurrence of gastric mucosa inflammation but also to gastric ulcer and cancer. H. pylori 
contains an active antioxidative system, which not only neutralizes free radicals but also 
synthesizes specific VacA toxin, which leads to destruction and apoptosis of the cells. 
A specific system of bacterial CagA genes has a special role in carcinogenesis. There is 
an increasing number of reports describing lesions in the circulatory system, pancreas, 
or the skin, connected with H. pylori infection. Liver colonization by H. pylori happens 
after transmission of the bacteria from the stomach, with blood, through the portal vein 
or directly through the bile ducts. The bacteria promote liver function deterioration in 
the course of toxic injury, autoimmune inflammation, chronic HBV, and HCV infection. 
Infections among people with liver cirrhosis are especially dangerous. In this group of 
patients, H. pylori infection may significantly worsen liver function, leading to hyper-
ammonemia, increased portal pressure, and development of esophageal varices. Thus, 
testing for and treating this infection among patients with liver cirrhosis is especially 
important.
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1. Introduction
Helicobacter pylori (H. pylori) is a microaerophile described for the first time by Marshal and 
Warren in 1982. This Gram-negative bacillus is resistant to the activity of gastric acid. Active, 
vegetative form of the bacteria is spiral, while the sporulation form is granular [1]. The bacte-
rium contains stable DNA and a system of very effective DNA repair.
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In developed countries, infection by these bacteria is detected in about 50% of the population, 
while in developing countries, the percentage may even reach 90% [2]. Still, however, there 
are no definitive pointers as to risk factors of H. pylori infection.
H. pylori produces high amounts of ureases, enzymes catalyzing urea decomposition to 
ammonia. This is especially important for the neutralization of hydrochloric acid in the stom-
ach, which contributes to the growth of the bacteria. Bacteria demonstrate also the ability to 
pump out H+ ions from cells. This leads to changes in the pH in the stomach, which in turn 
causes destruction of gastric mucosa.
H. pylori has an active antioxidizing system, which neutralizes free radicals. The system con-
tains catalase, superoxide dismutase, and specific proteins MdaB and NapA.
Bacterial DNA contains genes encoding cytotoxin synthesis system. VacA toxin (vacuolating 
toxin) is encoded by a changing system of genes in 40–60% of bacterial strains. This under-
lies different toxic properties. In epithelial cells, VacA promotes fusion of several lysosomes 
and formation of large vacuoles, which changes the construction of cytoskeleton. VacA toxin 
induces apoptosis of epithelial cells and shows highly immunogenic properties.
Specific system of CagA genes encodes synthesis of CagA toxin, demonstrating properties reor-
ganizing cytoskeleton and cell shape. Moreover, the toxin controls transcription and proliferation 
of the cell, as well as inflammatory reaction. CagA toxin plays a very important role in carcino-
genesis in the stomach and other organs, when CagA-synthesizing H. pylori is detected [3, 4].
H. pylori is mainly present on the surface of epithelial cells of the mucosa, in the prepyloric 
part of the stomach. It has cilia allowing transport into intercellular spaces, and thanks to 
produced adhesins, it adheres to cell surface [1].
H. pylori infection influences local (in the gastric mucosa) and systemic increase in proinflam-
matory cytokines IL-1, -2, -4, -6, -8, -10, -17, interferon-β, and TNF-α [5]. This leads not only to 
development of local inflammatory reaction, but also potentiates generalized inflammatory 
reactions in the organism. H. pylori causes chronic atrophic gastritis, metaplasia, and dyspla-
sia, leading to the development of gastric cancer. According to World Health Organization 
(WHO), the bacteria are a class I carcinogen. H. pylori may also potentiate extragastric organ 
disturbances, exacerbating the diseases of cardiovascular system or metabolic diseases, dete-
riorating normal function of the liver, especially in patients with cirrhosis [6].
2. Organ pathologies connected with H. pylori infection
H. pylori infection, especially in the case of strains producing CagA toxin, promotes devel-
opment of coronary sclerosis and increases the probability of angina pectoris and cardiac 
infarct [7]. Effect of CagA toxin on promotion of sclerotic changes in coronary arteries leads 
to exacerbation of coronary disease, which increases mortality caused by circulatory failure 
in the group of patients infected with these bacteria and not subjected to eradication [8, 9].
H. pylori infection among patients with type 2 diabetes presents more seriously compared to 
patients without diabetes [10]. Moreover, impact of this infection onto the development of 
chronic pancreatitis has been reported, which indirectly affects liver function [11].
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H. pylori infection is associated with many skin conditions. Higher incidence of chronic urti-
caria, acne rosacea, idiopathic thrombocytopatic purpura, psoriasis, atopic dermatitis, and 
some other dermatological conditions among patients infected with H. pylori has been dem-
onstrated [12].
3. Liver injury
Liver colonization by H. pylori happens after transmission of the bacteria from the stomach, 
with blood, through the portal vein or directly through the bile ducts [13].
Experimental studies performed on mice and rats infected with H. pylori have shown the 
effect of this infection onto up triggered fibrosis and development of liver cirrhosis [14]. One 
of the first studies performed in patients with chronic liver injury pointed to the presence 
of Helicobacter genus bacteria in the liver tissue in 26% of patients [15]. Current studies in 
patients infected with HBV, HCV, and patients with chronic noninfectious liver conditions 
point to much higher incidence of H. pylori or bacterial DNA in the liver tissue. Infections are 
thought to occur in effect of disturbances in patients’ immune functions [16]. Both experimen-
tal and clinical studies demonstrate unfavorable effect of H. pylori infection onto the course 
of liver injury, especially exacerbated fibrosis. One of the reasons for this is the influence of 
infection onto metabolic changes connected with carbohydrate turnover, synthesis of high-
energy compounds (mainly ATP), and increased concentration of proinflammatory cytokines.
4. Chronic HBV and HCV infections
The frequency of H. pylori infection among patients with chronic hepatitis B is around 30–80% 
[17]. H. pylori infection is confirmed in 79% of patients with postinflammatory liver cirrhosis 
connected with HBV infection [18]. Favorable effect of H. pylori eradication on the course 
of the disease, including increased platelet count, has been demonstrated in the studies on 
patients chronically infected with HBV, with compensated liver cirrhosis and thrombocyto-
penia [19].
Among people chronically infected with HBV with primary liver cancer, H. pylori infection 
is found in 69% of patients. In the group of patients with primary liver cancer, but without 
HBV infection, H. pylori infection is much less frequent, as it is found in 33% of patients. 
These observations consistently point to unfavorable effect of H. pylori infection among 
HBV-infected patients with liver cirrhosis onto the risk of occurrence of primary liver cancer. 
Frequency of H. pylori infection among patients with chronic hepatitis B correlates with the 
incidence of hepatocellular cancer, both in men and women [20]. Among this type of patients, 
fast progression of inflammatory changes in the liver is observed, as well as intensified fibro-
sis, which promotes occurrence of primary neoplastic lesions [17, 21].
Among patients infected with H. pylori and HBV, liver function is impaired (prothrombin time 
is extended, and AST activity and bilirubin concentration increased), and esophageal varices, 
ascites and hyperammonemia with hepatic encephalopathy occur much more frequently [18].
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Evaluation of H. pylori infection among patients with chronic HCV infection is difficult. Some 
authors state that the frequency of H. pylori infection among the patients in this group is about 
38%. Around 45% of those result from CagA-synthesizing bacteria. No significant differences 
are found in the morphological picture of HCV-infected liver, between patients with or with-
out H. pylori infection. There is also no correlation between H. pylori infection and IL 28B poly-
morphism [22]. However, many other authors present other observations. H. pylori infection 
may be present in even 70% of patients chronically infected with HCV [23]. Meta-analysis of 
20 studies demonstrated higher incidence of H. pylori infection among HCV-positive patients, 
compared to persons without viral infection [17, 24]. Much higher fibrosis, loss of cellular 
proteins, and glycogen was found in morphological studies of the liver from HCV-positive 
patients, if those were coinfected with H. pylori, compared to those without coinfection [25].
5. Autoimmune diseases and liver steatosis
Studies performed among patients with chronic viral autoimmune and toxic hepatitis 
and coexisting H. pylori infection demonstrated improvement in liver function, including 
decreased ALT and AST activity, after effective eradication of bacteria [26].
H. pylori infection is found in 20–50% of patients with AIH. Among patients with PBC, H. 
pylori infection is found more frequently than among people from the control group (54 vs. 
31% p = 0.01). However, the effect of this infection on the course of PBC has not been eluci-
dated [27].
Infection by these bacteria worsens the course of underlying disease; however, pathogenesis 
is not completely clear [28, 29]. In the group of patients with PBC and AIH, H. pylori infection 
may lead to precipitous, unfavorable progression of the disease [30].
Reports on the effect of H. pylori infection on lipid turnover disturbances, leading to hyper-
triglyceridemia and hypercholesterolemia with concomitant decrease of HDL level, are 
published more and more frequently. This is especially important for the metabolism of 
hepatocytes and their steatosis, as well as in the process of liver fibrosis [31]. Many reports 
point to the fact that H. pylori infection hastens the development of NAFLD [32]. It has been 
demonstrated that H. pylori infection among patients with NAFL results in the development 
of NASH. Eradication of the bacteria significantly facilitates the treatment of liver steatosis 
[33]. Moreover, it has been found that H. pylori infection and steatosis constitute the risk of 
more frequent occurrence of cholecystolithiasis and choledocholithiasis [34].
6. Liver cirrhosis, hepatocellular carcinoma (HCC), and 
cholangiocarcinoma (CCC)
Inflammation of gastric mucosa is a frequent complication of liver cirrhosis. Usually, occur-
rence of chronic inflammation is observed, described as portal gastropathy. H. pylori infection 
in the group of patients with liver cirrhosis impacts exacerbation of inflammatory changes 
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in the stomach, which in turn worsens liver function. This is especially dangerous among 
patients with advanced liver injury. Studies performed on this group of patients point to high 
significance of cytopathic effect of H. pylori onto hepatocytes [16, 35]. H. pylori infection affects 
increase of portal tension, which is one of the main etiologies of development of esophageal 
varices [6, 36]. In effect, correlation between the frequency of H. pylori infection and advance-
ment of esophageal varices is observed [37].
Although in some studies more frequent H. pylori infection among patients with liver cir-
rhosis cannot be confirmed [38]; however, meta-analysis was performed that included mainly 
patients with alcoholic liver cirrhosis, which argues for much more frequent occurrence of 
these bacteria among such patients. H. pylori infection is much more frequent among patients 
with postinflammatory liver cirrhosis (connected with HBV or HCV infection) [37]. Incidence 
of H. pylori infection among patients with liver cirrhosis and concomitant HCV infection 
increases proportionally to progressing liver failure [39]. Moreover, it has been demonstrated 
that the highest percentage of people infected with H. pylori among those with HCV infec-
tion is observed in the case of patients in whom HCC developed [17, 24]. Many pieces of 
information argue that concomitant infection with H. pylori and HCV increases the incidence 
of HCC. Eradication of these bacteria in patients with cirrhotic liver leads to the increase of 
platelet count and improves efficacy of antiviral therapy [23, 40]. In the current setting, when 
direct-acting antivirals are commonly used, this is probably not so important; however, such 
studies have not been performed.
H. pylori catalyzes the reaction of urea decomposition to ammonia and carbon dioxide; how-
ever, among patients with subclinical hepatic encephalopathy, infection with these bacteria 
does not change the concentration of ammonia in the blood [41]. These observations are 
inconsistent, because among patients with liver cirrhosis, especially postinflammatory cir-
rhosis, more frequent occurrence of symptomatic hepatic encephalopathy with hyperammo-
nemia is observed in the case of patients infected with H. pylori, compared to patients without 
this infection [37, 42]. In the studies performed in patients with liver cirrhosis, a correlation 
between increasing ammonia blood concentration and H. pylori infection has been demon-
strated. Moreover, ammonia blood concentration was higher among patients with liver cir-
rhosis infected with H. pylori, compared to patients not infected with these bacteria [37].
In experimental studies performed on dogs, an association between H. pylori infection and 
occurrence of hepatocellular carcinoma (HCC) has been evidenced [43]. Evaluation of the 
effect of H. pylori infection on liver carcinogenesis in humans shows that in 58% of patients 
with HCC and in 62% of patients with CCC in the liver tissue surrounding focal lesion, DNA 
of these bacteria can be detected [44]. H. pylori may disturb the balance between hepatocyte 
proliferation and activity of apoptosis in the liver. In effect, there is a higher risk of occurrence 
of neoplastic cells in the liver [45].
In the pathogenesis of biliary duct carcinoma, H. pylori infection affects proliferation of biliary 
duct epithelium and development of inflammatory reaction in these cells. Activation of reac-
tive oxygen species (oxidative stress) and reactive nitrogen species, mainly 8-nitroguanine, 
in the cells is detected. These reactions damage DNA of stem cells, playing a key role in 
carcinogenesis [46]. A special role in the development of bile duct carcinoma is attributed to 
H. pylori producing CagA toxin [47].




H. pylori infection is detected significantly more often among patients with chronic liver injury. 
This is especially dangerous in patients with liver cirrhosis. In this group of patients, H. pylori 
infection may significantly worsen liver function, affecting hyperammonemia, increase in 
portal pressure, and development of esophageal varices. Testing for and treating this infection 
is of paramount importance for these patients.
Current research on the impact of H. pylori infection in patients with chronic liver damage 
is inadequate. This points to the desirability of further research, particularly among patients 
with severe liver damage.
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